Replies to post #158269 on Biotech Values

[imnot6]

Can anyone translate this for me? TIA

"...two of the original reasons I came to OGD, to help pave the way for extension of generics across the entire therapeutic spectrum from solid oral dosage forms to complex drugs, from pills to inhalers to topical creams, and to address issues such as pill size, shape, color and the importance this may have for patients who use generics, would be challenged by resources needed for application to other extremely important efforts of the chemistry group in moving to OPQ."

[DewDiligence]

Kathleen Uhl is new acting director of OGD* while FDA searches for permanent hire:

http://in.reuters.com/article/2013/03/19/us-fda-generics-director-idINBRE92I0S120130319

Janet Woodcock (head of CDER) had been the acting OGD director since Gregory Geba resigned last week.

*Office of Generic Drugs.